reserved.
Interleukin-9 Expression in Human Malignant
To test the possibility that interleukin-9 (IL-9). the human homologue of the mouse T-cell growth factor P40, may be involved in the pathogenesis of human lymphomas, we examined 11-9 expression in a variety of tumors both by Northern blot analysis and by in situ hybridization. Of 18 6-cell nomHodgkin's lymphomas and 11 peripheral T-cell lymphomas, none expressed IL-9 message. By contrast, IL-9 message was found in two of six cases of large cell anaplastic lymphoma (LCAL) and in 6 of 13 cases of Hodgkin's disease (HD). In HD the strongest signals were observed in Hodgkin (H) and Sternberg-Reed (SR) cells, but 11-9 mRNA was also EMATOPOIETIC and lymphoid cell compartments H are regulated by a complex network of interacting cytokines.' The colony-stimulating factors (CSFs) and the interleukins (ILs) 1 through 7 have been shown to play important roles in normal proliferation, differentiation, and activation of several hematopoietic and lymphoid lineages.' Moreover, it has been shown that excessive autocrine or paracrine cytokine production that was found in a variety of hematopoietic and lymphoid malignancies334 may not only cause a number of clinically relevant symptoms' but may also be a possible basis for continuous neoplastic cell growth:
The newly described cytokine P40 has been shown to cause antigen-independent proliferation as well as prolonged survival of some murine T-cell clones?* Growth factor activity of this cytokine was additionally demonstrated for mouse mast cells in combination with IL-3 and IL-4: as well as for murine immature thymocytes in combination with IL-2." P40 production was ascribed to anti-CD3 or mitogen-activated normal CD4' T cells."
The human homologue of P40, which was also shown to be preferentially expressed by the CD4+ T-cell subset,'* was first discovered by its mitogenic activity on a megakaqoblastic cell line.I3 Subsequently it was shown to support growth of erythroid blast-forming units, suggesting that responsiveness to P40 might appear in an early progenitor cell population before the determination of erythroid commitment.I4 As a consequence of these multiple activities, P40
was recently redesignated as IL-9.
Here we demonstrate a unique pattern of expression of IL-9 in human malignant lymphomas, which suggests the possible involvement of IL-9 in the pathogenesis of Hodgkin's disease (HD) and large cell anaplastic lymphoma (LCAL).
MATERIALS AND METHODS

Tissues
Forty-five cases of malignant lymphomas were investigated (Table 1) . One part of the material was routinely processed by formalin fixation. Paraffin sections were stained for HE, Giemsa, PAS, and for Gomori silver impregnation. Another part of the material was snap-frozen in liquid nitrogen directly after surgical removal and stored at -80°C. Cryostate sections were used for immunophenotyping with monoclonal antibodies (CD2, CD3, detected in small lymphocytic cells. A search for IL-9 message in a panel of 20 cell lines derived both from hematopoietic and nonhematopoietic tumors confirmed the unique association of IL-9 expression with HD and LCAL in as much as the only two cell lines with IL-9 message were derived from cases of HD and LCAL. These results suggest that IL-9 is not involved as an autocrine growth factor in the pathogenesis of most B-and T-cell lymphomas, but that it may play a role in HD and LCAL. @ 1991 by The American Society of Hematology.
CD4, CD5, CD7, CD8, CD15, CD22, CD25, CD30) and for in situ hybridization.
Altogether, 16 cases of low-grade and high-grade B-cell lymphomas were investigated (one chronic lymphocytic leukemia of B type, one chronic lymphocytic leukemia of B type/immunocytoma, two hairy cell leukemias, six centroblastic-centrocytic lymphomas, two centrocytic lymphomas, one centroblastic lymphoma, two Burkitt lymphomas, and one lymphoblastic lymphoma B type).
Eleven cases were diagnosed as peripheral T-cell lymphomas (six pleomorphic T-cell lymphomas, four angioimmunoblastic lymphadenopathy, and one lymphoepitheloid lymphoma).
Six cases were diagnosed as LCAL, three of which were of T-cell type and two of B e l l type. The cellular origin of one case of LCAL could not be identified.
Thirteen cases were diagnosed as HD (one lymphocyte predominance, eight nodular sclerosis, three mixed cellularity, and one lymphocyte depletion).
Cell Lines, Media, and Mitogens
The investigated cell lines are listed in Table 2 tlSH, in situ hybridization; nd, not done. streptomycin, and L-glutamine. Cultures were kept at 37°C in a 5% to 7.5% CO, humidified atmosphere at 0.1 to 0.5 x lo6 cells/mL. The medium was changed at daily intervals. Cell viability as determined by trypan blue exclusion was always higher than 95%.
PHA and PMA were obtained from Sigma (Munich, Germany) and used at concentrations of 1 pg/mL and 10 ng/mL, respectively.
RNA Preparation and Northern Blotting
Frozen tumor material was homogenized and suspended in guanidine thiocyanate buffer followed by cesium-chloride gradient ~entrifugation.'**'~ Twenty micrograms of total RNA per lane was size-fractionated by electrophoresis in 6% formaldehyde/l.5% agarose gels?' Before RNA transfer to nylon membranes (Hybond; Amersham, Braunschweig, Germany), the gels were stained with ethidium bromide to verify RNA contents. Equal amounts of total RNA from stimulated PBL (PMA 10 ng/mL [Sigma], Caionophore-A 23187 100 ng/mL [Sigma]) were used as controls.
Probes
The cDNA of IL-9 was cloned by Renauld et al" and the coding region of IL-9 was subcloned into transcription vectors (PSPT 18 and PSPT 19; Boehringer, Mannheim, Germany).
The 32P-and "S-labeled sense and antisense cRNA probes were generated by in vitro transcription with T7 RNA-Polymerase (Boehringer) to a specific activity of 1 to 5 x 10' c p d p g cRNA." RNA quality and quantity control was performed by use of the human @-actin probe?* use only.
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Slides were subsequently dipped in Ilford K2 Emulsion, incubated for 3 days at 4"C, developed in Kodak D19 developer, and Giemsa-stained.
Controls were performed on RNAse-treated fixed cryostate sections. For each case a sense cRNA probe was used.
RESULTS
Northern Analysis and In Situ Hybridization
IL-9 expression was examined by Northern blot analysis of total RNA isolated from B-cell lymphomas (n = 18), peripheral T-cell lymphomas (n = ll), LCAL (n = 6), and HD (n = 13).
B-cell lymphomas and peripheral T-cell lymphomas were negative, but two cases of LCAL and six cases of HD showed weak, moderate, or strong positivity (Table 1 and Fig 1A) . In several cases, the signal was even stronger than that obtained in PBL maximally stimulated with PMA and PHA. The use of equal quantities of RNA is documented by rehybridization of the same blot with the p-actin probe ( Fig  1B) .
Examination analysis turned out to be positive by ISH, which increased the proportion of positive cases to over 50%. As a number of samples could not be tested by ISH, the actual proportion may be still higher. In each individual case control slides were more or less completely negative due to the high stringency during hybridization and posthybridization ( Fig  3B) .
A variety of human tumor cell lines maintained in vitro were examined for constitutive and inducible IL-9 expression (Table 2) . Cell lines were stimulated with PMA and PHA or with PMA alone. Of 16 hematopoietic cell lines that were examined, only two expressed IL-9 message: SKA, an LCAL-derived cell line and U28, an HD-derived cell line. In SKA, IL-9 message was expressed constitutively and could be slightly increased by mitogen stimulation (Fig 4) . By contrast, in L428, it was expressed only after stimulation with PMA/ PHA. Under these conditions, the signal intensity, which IL-9 expression in tumor cell lines.
-0.7 (Fig 5) . Four nonhematopoietic cell lines were found negative even after stimulation with PMA. Because there is heterogeneity in the clinical and pathologic spectrum of HD including different phenotypic properties, there may also be a heterogeneity in the cellular origin of the H and SR cells. This can possibly cause a heterogeneity in the cytokine production and expression.
Under normal conditions, IL-9 is essentially produced by activated CD4+ T cells. Thus, it is tempting to consider its expression as a marker for this cell lineage within the lymphoid system. Although the number of cases examined in our study is still limited, our results lend some support to this idea because the two cases of LCAL and six of the seven cases of HD that were IL-9-positive were of T-cell type. However, there was one exception, namely a case of HD that showed B-lineage antigens on the H cells and strong IL-9 positivity in Northern blot analysis; this case was diagnosed as HD, lymphocyte predominance type, with only scattered H and RS cells.
The strong IL-9 signals detected in Northern blots seemed unlikely to be derived solely from H and RS cells as these cells comprise only a small proportion of the total cellular mass, especially in the case of HD, lymphocyte predominance type.
ISH documented the expression of IL-9 in large atypical cells in HD, which are most probably H and RS cells, and additionally in small lymphocytes. This observation further underlines the view that activated T lymphocytes in HD may be the precursor of H and SR cells, and thus may belong to the tumor cell clone that was shown earlier by Southern blot experimenkM
Although not all cases of HD could be investigated in parallel for Northern blot and ISH, it is clear that all cases positive in Northern blots had clear signals in ISH. Furthermore, both cases negative in Northern blot had detectable signals using ISH.
It is now well established that transfer of growth factor genes into previously immortalized cell lines results in autonomous growth and t~morigenicity,~'.~' a finding recently extended to a mouse T-cell line transfected with IL-9. CD4' mouse T cells were stimulated and clonally amplified. These cells grew continuously with exogenously added mouse P40. After transfection of the clonally amplified p40/11-9-dependent cells with the p40/IL-9 gene under the control of a eukaryotic expression vector, these cells grew independently and produced malignant lymphomas after intraperitoneal appli~ation.~~ The latter observation raises the possibility that the selective expression of IL-9 in HD and LCAL may be involved in autocrine growth of these tumors. Another possibility that needs to be further investigated is that overexpression of IL-9 in vivo may lead to unique symptoms such as those recently reported for ILJ-positive cases of HD, which were all associated with eosinophilia. 40 Finally, it will be of interest to initiate a prospective study to investigate possible correlations between IL-9 expression and clinical outcome.
